Recruitment

Recruitment Status
Active, not recruiting
Estimated Enrollment
100

Inclusion Criteria

cirrhotic patients presented with actively bleeding
cirrhotic patients presented with actively bleeding

Exclusion Criteria

other sources of UGIB than esophageal varices, hepatic encephalopathy or hepatocellular carcinoma (HCC)
other sources of UGIB than esophageal varices, hepatic encephalopathy or hepatocellular carcinoma (HCC)

Summary

Conditions
Bleeding Esophageal Varices
Type
Interventional
Phase
Phase 3
Design
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: None (Open Label)
  • Primary Purpose: Treatment

Participation Requirements

Age
Younger than 125 years
Gender
Both males and females

Description

Endoscopic Injection Sclerotherapy versus N-butyl-2-cyanoacrylate Injection in the Management of Actively Bleeding Esophageal Varices

Endoscopic Injection Sclerotherapy versus N-butyl-2-cyanoacrylate Injection in the Management of Actively Bleeding Esophageal Varices

Inclusion Criteria

cirrhotic patients presented with actively bleeding
cirrhotic patients presented with actively bleeding

Exclusion Criteria

other sources of UGIB than esophageal varices, hepatic encephalopathy or hepatocellular carcinoma (HCC)
other sources of UGIB than esophageal varices, hepatic encephalopathy or hepatocellular carcinoma (HCC)

Locations

Tanta
Tanta

Tracking Information

NCT #
NCT03388125
Collaborators
Not Provided
Investigators
  • Principal Investigator: Mohamed Alsebaey, MD Gastroenterology Study Director: Mohamed Abdelraouf, MD Gastroenterology Study Director: Sherief Abd-Elsalam, MD Hepatology and Gastroenterology
  • Mohamed Alsebaey, MD Gastroenterology Study Director: Mohamed Abdelraouf, MD Gastroenterology Study Director: Sherief Abd-Elsalam, MD Hepatology and Gastroenterology